The study is comparing FLAM vs. cytarabine and mitoxantrone (AM) in patients with MCL-1-dependent R/R AML as demonstrated by NOXA-BH3 priming of ≥40% by mitochondrial profiling of the bone marrow. The gene discussed is PMAIP1; the disease is acute myeloid leukemia.